Pancreatic large cell neuroendocrine carcinoma

Summary

Pancreatic large cell neuroendocrine carcinoma (MONDO:0006347) is a cancer. A subtype of large cell neuroendocrine carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pancreatic large cell neuroendocrine carcinoma
Mondo ID	MONDO:0006347
EFO	EFO:1000442
NCIT	C95582
UMLS	C2987239
MedGen	459465
GARD	0024376
Anatomy (UBERON)	UBERON:0001264
Is cancer (heuristic)	yes

Also known as: large cell neuroendocrine carcinoma of pancreas · pancreas large cell neuroendocrine carcinoma · pancreatic large cell NEC · pancreatic large cell NEC G3 · pancreatic large cell neuroendocrine carcinoma

Data availability: 1 cell line.

Disease family

This is a subtype of large cell neuroendocrine carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › neuroendocrine carcinoma › large cell neuroendocrine carcinoma › pancreatic large cell neuroendocrine carcinoma

Related subtypes (5): thymic large cell neuroendocrine carcinoma, ovarian large-cell neuroendocrine carcinoma, breast large cell neuroendocrine carcinoma, pulmonary large cell neuroendocrine carcinoma, cervical large cell neuroendocrine carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.